Medivir AB (publ) (STO:MVIR)

Market Cap	1.02B +446.8%
Revenue (ttm)	9.01M +151.3%
Net Income	-90.50M
EPS	-0.39
Shares Out	538.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,132,734
Average Volume	2,924,106
Open	2.035
Previous Close	2.035
Day's Range	1.840 - 2.035
52-Week Range	0.340 - 2.885
Beta	0.11
RSI	47.49
Earnings Date	Apr 29, 2026

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MVIR

Financial Performance

In 2025, Medivir AB's revenue was 8.51 million, an increase of 144.14% compared to the previous year's 3.48 million. Losses were -94.40 million, -23.45% less than in 2024.